Aeris Active virus killer approved for sale in the UK
Australian independent test confirms Aeris Active is effective against Coronavirus in 60 seconds
2 June 2020Why coronavirus may hit Australia worse than in China | NEWS UPDATE | Thursday 27th Feb
2 June 2020As published in The Sentiment
Written by Alfred Chan
March 5, 2020
Environmental biotech company Aeris Environmental (ASX: AEI) has seen no shortage of demand for its Aeris Active disinfectant but is set to capitalise on global demand further with approval from the UK Poison Control Centre for sale in the UK.
With independent labs already confirming that Aeris Active is more than 99.99% effective in deactivating COVID-19, Aeris’ share price has doubled in the past month.
Now with the ability to distribute its patented hospital-grade disinfectant to Europe’s second largest population of more than 65 million people, Aeris is in a position to selectively choose its more profitable markets.
“Aeris is pleased to be able to announce the expansion of its breakthrough product Aeris Active into the UK, as part of the growth of our global distribution footprint of approved countries for Aeris’ proprietary environmental hygiene portfolio,” said Aeris CEO, Peter Bush.
“The key features of Aeris’ rapid, broad spectrum kill, environmental profile and, most importantly, the unique validation of our “multi-touch” residual protection is driving rapidly increasing demand from many key international markets.”
Beyond just proving effective against the most recent coronavirus outbreak, Aeris has also recently had an independent lab confirm Aeris Active to be more than 99.99% effective in killing the influenza virus which kills more than 650,000 people annually according to the World Health Organisation.
With its virucidal and bactericidal properties, it is furthermore effective against norovirus which is the virus that causes gastro and is responsible for more than 200,000 deaths annually.
As of today, COVID-19 has been responsible for 3,254 deaths in two months of its outbreak which has it on track for significantly less deaths than the influenza virus or norovirus.
Based on the significant increase in profile for Aeris over the past two months, Bush commented that the significant rise in sales for Aeris Active will have a material impact on their FY20 results.
Following news of approval for the sale of Aeris Active in the UK, shares in AEI rose to a high of $0.71, a rise of 10.9% on their previous day’s close of $0.64.
Alfred Chan is an Analyst at Emerald Financial, specialising in ASX-listed small cap companies.